Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects : Phase 1 Study
© 2020 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology..
This study evaluated the effect of a small-tablet formulation of opicapone for use in clinical trials in Japan on the pharmacokinetics of levodopa (l-dopa) and 3-O-methyldopa (3-OMD). In an open-label, 3-period, single-sequence crossover phase 1 study in 80 healthy Japanese males (aged 20-45 years; body mass index, 18.5 to <30.0 kg/m2 ), 10 mg of l-dopa/carbidopa 100 was administered 3 times daily on day 0 (period 1) and day 12 (period 3), and opicapone tablets (5, 10, 25, or 50 mg; n = 20 each group) were administered once daily for 11 days (period 2). During periods 1 and 3, plasma concentrations of l-dopa and 3-OMD were measured and pharmacokinetic parameters (maximum observed plasma concentration, time at which maximum concentration was observed, area under the plasma concentration-time curve from time 0 to 5 hours [AUC5h ] and from time 0 to 24 hours [AUC24h ] following each dose, terminal half-life) of plasma l-dopa and 3-OMD were determined along with the geometric mean ratio (period 3/period 1) of AUC24h for l-dopa and 3-OMD. Maximum concentration of l-dopa for the first, second, or third doses of l-dopa/carbidopa did not significantly increase with increasing opicapone dose. The AUC of l-dopa increased with increasing opicapone dose but tended toward a peak plateau with opicapone doses of 25 mg and higher. Geometric mean ratios (90% confidence intervals) of AUC24h were 5 mg, 1.16 (1.10-1.21); 10 mg, 1.26 (1.23-1.30); 25 mg, 1.51 (1.44-1.57); 50 mg, 1.60 (1.54-1.66). Opicapone tablets were well tolerated. In Japanese healthy subjects, increases in plasma exposure to l-dopa appear to level off with opicapone doses of 25 mg and higher, which may be relevant for optimal dosing among Japanese patients with Parkinson disease.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Clinical pharmacology in drug development - 10(2021), 2 vom: 24. Feb., Seite 180-189 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Nomoto, Masahiro [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.12.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/cpdd.799 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309987059 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309987059 | ||
003 | DE-627 | ||
005 | 20231225135120.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/cpdd.799 |2 doi | |
028 | 5 | 2 | |a pubmed24n1033.xml |
035 | |a (DE-627)NLM309987059 | ||
035 | |a (NLM)32416054 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Nomoto, Masahiro |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects |b Phase 1 Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.12.2021 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology. | ||
520 | |a This study evaluated the effect of a small-tablet formulation of opicapone for use in clinical trials in Japan on the pharmacokinetics of levodopa (l-dopa) and 3-O-methyldopa (3-OMD). In an open-label, 3-period, single-sequence crossover phase 1 study in 80 healthy Japanese males (aged 20-45 years; body mass index, 18.5 to <30.0 kg/m2 ), 10 mg of l-dopa/carbidopa 100 was administered 3 times daily on day 0 (period 1) and day 12 (period 3), and opicapone tablets (5, 10, 25, or 50 mg; n = 20 each group) were administered once daily for 11 days (period 2). During periods 1 and 3, plasma concentrations of l-dopa and 3-OMD were measured and pharmacokinetic parameters (maximum observed plasma concentration, time at which maximum concentration was observed, area under the plasma concentration-time curve from time 0 to 5 hours [AUC5h ] and from time 0 to 24 hours [AUC24h ] following each dose, terminal half-life) of plasma l-dopa and 3-OMD were determined along with the geometric mean ratio (period 3/period 1) of AUC24h for l-dopa and 3-OMD. Maximum concentration of l-dopa for the first, second, or third doses of l-dopa/carbidopa did not significantly increase with increasing opicapone dose. The AUC of l-dopa increased with increasing opicapone dose but tended toward a peak plateau with opicapone doses of 25 mg and higher. Geometric mean ratios (90% confidence intervals) of AUC24h were 5 mg, 1.16 (1.10-1.21); 10 mg, 1.26 (1.23-1.30); 25 mg, 1.51 (1.44-1.57); 50 mg, 1.60 (1.54-1.66). Opicapone tablets were well tolerated. In Japanese healthy subjects, increases in plasma exposure to l-dopa appear to level off with opicapone doses of 25 mg and higher, which may be relevant for optimal dosing among Japanese patients with Parkinson disease | ||
650 | 4 | |a Clinical Trial, Phase I | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a 3-OMD | |
650 | 4 | |a COMT inhibitor | |
650 | 4 | |a Japanese | |
650 | 4 | |a Parkinson disease | |
650 | 4 | |a levodopa | |
650 | 4 | |a opicapone | |
650 | 4 | |a pharmacokinetic | |
650 | 4 | |a phase 1 | |
650 | 7 | |a Antiparkinson Agents |2 NLM | |
650 | 7 | |a Catechol O-Methyltransferase Inhibitors |2 NLM | |
650 | 7 | |a Drug Combinations |2 NLM | |
650 | 7 | |a Oxadiazoles |2 NLM | |
650 | 7 | |a Tablets |2 NLM | |
650 | 7 | |a carbidopa, levodopa drug combination |2 NLM | |
650 | 7 | |a Tyrosine |2 NLM | |
650 | 7 | |a 42HK56048U |2 NLM | |
650 | 7 | |a Levodopa |2 NLM | |
650 | 7 | |a 46627O600J |2 NLM | |
650 | 7 | |a Carbidopa |2 NLM | |
650 | 7 | |a MNX7R8C5VO |2 NLM | |
650 | 7 | |a 3-methoxytyrosine |2 NLM | |
650 | 7 | |a V3O7J20DWN |2 NLM | |
650 | 7 | |a opicapone |2 NLM | |
650 | 7 | |a Y5929UIJ5N |2 NLM | |
700 | 1 | |a Takeda, Atsushi |e verfasserin |4 aut | |
700 | 1 | |a Iwai, Katsuaki |e verfasserin |4 aut | |
700 | 1 | |a Nishimura, Akihisa |e verfasserin |4 aut | |
700 | 1 | |a Hattori, Nobutaka |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology in drug development |d 2012 |g 10(2021), 2 vom: 24. Feb., Seite 180-189 |w (DE-627)NLM250185032 |x 2160-7648 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2021 |g number:2 |g day:24 |g month:02 |g pages:180-189 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpdd.799 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2021 |e 2 |b 24 |c 02 |h 180-189 |